or epidemiological suspicion. Comorbid diagnoses, clinical features, radiological and laboratory investigations, treatments and outcomes were reviewed from medical records. Univariate analysis was performed to identify factors related to death. We performed descriptive statistics on percentage (%), median, mean and range. A p value of <0.05 was consideré significant
Results
The PTB incidence rate in the group st udied was e stimated at 0,12, increasing 85% from 2006 to 2016. The median/mean age were 40/38 years ( range: 14-74 years), with a pre dominance of males (62%). The median duration of le ngth of ICU stay was 7 ( range: 1-35) days. 76% had evolved to Ai ds for more than a year . 95% presented hypoalbuminemia (< a 3,5 g/l), weight loss >10% in 6 last months and/or Karnofsky score ≤50. Only 10% were receivi ng hi ghly active anti retrovi ral thera py (HAART). 7% had LT CD4 ≥200 cell s/mm3, none of them died. 93% had LT CD4 <200 cells and 50% died. 19% pre sent liver failure (LF) and 88% of them died. 8% were coinfected with hepatiti s C. Respiratory insufficiency (RI) was observed in 59% and 66% of them died. (Table 1) 
